## Gene Summary
KCNN1 (Potassium Calcium-Activated Channel Subfamily N Member 1) encodes a member of the small conductance calcium-activated potassium channel (SK) family. These channels are responsible for shaping the action potentials and regulating the excitability of a wide range of neuronal and non-neuronal cells. KCNN1 is predominately expressed in the central nervous system and plays a crucial role in modulating neuronal activity by affecting the membrane potential. This activity is calcium-dependent and sensitive to changes in intracellular calcium levels.

## Gene Drugs, Diseases, Phenotypes, and Pathways
KCNN1 is linked notably to diseases such as ataxia and epilepsy, rooted in its fundamental role in modulating neuronal excitability and firing patterns. Variants and dysfunction in this gene have been associated with alterations in neuronal stabilization, which can lead to the aforementioned disorders. In terms of pathways, KCNN1 is principally involved in the calcium signaling pathway, pivotal for numerous cellular processes beyond neuronal activity, including muscle function and intercellular communication. This calcium-based activation mechanism makes these channels essential targets for therapeutic research, particularly in neurological and neurodegenerative disorders.

## Pharmacogenetics
In pharmacogenetics, research on KCNN1 is still emerging, focusing on how variations in this gene could influence responses to drugs that target the small-conductance calcium-activated potassium channels. For instance, drugs like apamin, a bee venom-derived peptide, selectively blocks SK channels including those formed by KCNN1. Understanding how genetic differences in the KCNN1 gene affect the interaction and efficacy of such inhibitors could significantly impact clinical practices for treating neurological disorders. Research thus continues to evaluate the implications of KCNN1 variants on drug efficacy and safety, aiming to optimize personalized treatments in neurology.